How to win: Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

About this contract

Onasemnogene abeparvovec intravenous (Zolgensma®) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE’s technology appraisal programme, with an expected final guidance publication date in late 2026.

How to win contracts like this

• ✓Answer against the marking scheme, not the question text — NHS England scores each response, so map your evidence to the published criteria and weightings.
• ✓At £26,136,000, expect quality and social value to carry a large share of the score — price alone rarely wins services work.
• ✓Show recent, comparable delivery: name similar services contracts you've delivered for public bodies, with measurable outcomes.
• ✓Start early: it closes 8 July 2026 and a strong bid takes iteration.

BidWriter drafts your responses from your company profile, scores them against the marking scheme, and tracks your whole pipeline. Free to start — no card needed.

Related resources

Similar contracts